Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for the Treatment of Onychomycosis

by Benzinga Staff
May 11, 2012 9:58 AM | 1 min read | Make a Comment

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Apricus Biosciences (Nasdaq: APRI) announced today that Health Canada has granted the Company's request for a Pre-New Drug Submission ("Pre-NDS") meeting to obtain regulatory guidance from the agency for MycoVa™, the Company's topical treatment for onychomycosis, or nail fungus. The meeting is scheduled to take place July 18, 2012. Apricus Bio expects to obtain feedback from Health Canada regarding the suitability of its Phase 3 development program to support a New Drug Submission ("NDS") in Canada. In addition, the Company is seeking guidance from the US Food and Drug Administration and will be filing for guidance from the European Health Agency.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDAGlobal

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.